Silexion Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Selling, General & Admin	5.01	4.49	6.76	0.97	0.24	0.17
Research & Development	9.11	7.14	5.82	3.71	1.12	0.79
Operating Expenses	14.13	11.63	12.57	4.68	1.36	0.95
Operating Income	-14.13	-11.63	-12.57	-4.68	-1.36	-0.95
Interest Expense	-0.01	-0.01	-0.03	-	-0	-0
Interest & Investment Income	0.17	0.16	0.03	0.15	0	0.01
Currency Exchange Gain (Loss)	-0.14	-0.13	-0.25	-0.45	0	0.01
Other Non Operating Income (Expenses)	0.15	-0.29	-3.69	-0.1	-	-
Pretax Income	-13.96	-11.91	-16.51	-5.08	-1.36	-0.94
Income Tax Expense	-	0	0.01	0.03	-	-
Earnings From Continuing Operations	-13.96	-11.91	-16.52	-5.11	-1.36	-0.94
Minority Interest in Earnings	-	-	0.08	0.17	-	-
Net Income	-13.96	-11.91	-16.44	-4.94	-1.36	-0.94
Net Income to Common	-13.96	-11.91	-16.44	-4.94	-1.36	-0.94
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	0	0	-	-	-	-
Shares Outstanding (Diluted)	0	0	-	-	-	-
Shares Change	-	-	-	-	-	-
EPS (Basic)	-38.75	-89.60	-	-	-	-
EPS (Diluted)	-38.75	-89.60	-	-	-	-
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Free Cash Flow	-12.43	-10.83	-8.42	-4.54	-0.8	-0.91
Free Cash Flow Per Share	-34.51	-81.44	-	-	-	-
EBITDA	-14.12	-11.62	-12.55	-4.64	-1.36	-0.95
D&A For EBITDA	0.01	0.01	0.03	0.05	0	0
EBIT	-14.13	-11.63	-12.57	-4.68	-1.36	-0.95

SEC Filings: 10-K · 10-Q